Meeting
2023 ASCO Annual Meeting
Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.
Authors
Fei Ma
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Fei Ma , Yiqun Li , Herui Yao , Jingfen Wang , Quchang Ouyang , Jing Cheng , Xiaoyan Li , Xiao-Xiao Dinglin , Gongsheng Jin , Huan Zhou , Xinshuai Wang , Yuee Teng , Yongsheng Wang , Qi Dang , Jin Yang , Hui Hua Xiong , Weihong Zhao , Li Cai , Tingting Fu , Di Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT04487236
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1040)
DOI
10.1200/JCO.2023.41.16_suppl.1040
Abstract #
1040
Poster Bd #
261
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases.
First Author: Carey K. Anders
Poster
2021 ASCO Annual Meeting
Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.
First Author: Erica Michelle Stringer-Reasor
Poster
2021 ASCO Annual Meeting
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).
First Author: Tom Stinchcombe
Poster
2021 ASCO Annual Meeting
Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
First Author: Min Yan